542 related articles for article (PubMed ID: 27188563)
1. An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.
Acharya D; Bai F
Methods Mol Biol; 2016; 1435():249-91. PubMed ID: 27188563
[TBL] [Abstract][Full Text] [Related]
2. Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.
Throsby M; Ter Meulen J; Geuijen C; Goudsmit J; de Kruif J
Expert Rev Vaccines; 2007 Apr; 6(2):183-91. PubMed ID: 17408368
[TBL] [Abstract][Full Text] [Related]
3. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
[TBL] [Abstract][Full Text] [Related]
4. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.
Goo L; Debbink K; Kose N; Sapparapu G; Doyle MP; Wessel AW; Richner JM; Burgomaster KE; Larman BC; Dowd KA; Diamond MS; Crowe JE; Pierson TC
Nat Microbiol; 2019 Jan; 4(1):71-77. PubMed ID: 30455471
[TBL] [Abstract][Full Text] [Related]
5. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.
Spohn G; Jennings GT; Martina BE; Keller I; Beck M; Pumpens P; Osterhaus AD; Bachmann MF
Virol J; 2010 Jul; 7():146. PubMed ID: 20604940
[TBL] [Abstract][Full Text] [Related]
6. West Nile virus vaccines - current situation and future directions.
Ulbert S
Hum Vaccin Immunother; 2019; 15(10):2337-2342. PubMed ID: 31116691
[TBL] [Abstract][Full Text] [Related]
7. A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.
Van Hoeven N; Joshi SW; Nana GI; Bosco-Lauth A; Fox C; Bowen RA; Clements DE; Martyak T; Parks DE; Baldwin S; Reed SG; Coler RN
PLoS One; 2016; 11(2):e0149610. PubMed ID: 26901122
[TBL] [Abstract][Full Text] [Related]
8. Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.
Gershoni-Yahalom O; Landes S; Kleiman-Shoval S; Ben-Nathan D; Kam M; Lachmi BE; Khinich Y; Simanov M; Samina I; Eitan A; Cohen IR; Rager-Zisman B; Porgador A
Immunology; 2010 Aug; 130(4):527-35. PubMed ID: 20331473
[TBL] [Abstract][Full Text] [Related]
9. The molecular basis of antibody protection against West Nile virus.
Mehlhop E; Diamond MS
Curr Top Microbiol Immunol; 2008; 317():125-53. PubMed ID: 17990792
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G
Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus.
Verstrepen BE; Oostermeijer H; Fagrouch Z; van Heteren M; Niphuis H; Haaksma T; Kondova I; Bogers WM; de Filette M; Sanders N; Stertman L; Magnusson S; Lőrincz O; Lisziewicz J; Barzon L; Palù G; Diamond MS; Chabierski S; Ulbert S; Verschoor EJ
PLoS One; 2014; 9(11):e112568. PubMed ID: 25392925
[TBL] [Abstract][Full Text] [Related]
12. Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE).
Escribano-Romero E; Gamino V; Merino-Ramos T; Blázquez AB; Martín-Acebes MA; de Oya NJ; Gutiérrez-Guzmán AV; Escribano JM; Höfle U; Saiz JC
Vaccine; 2013 Sep; 31(41):4523-7. PubMed ID: 23933372
[TBL] [Abstract][Full Text] [Related]
13. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
Chu JH; Chiang CC; Ng ML
J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
[TBL] [Abstract][Full Text] [Related]
14. Progress on the development of therapeutics against West Nile virus.
Diamond MS
Antiviral Res; 2009 Sep; 83(3):214-27. PubMed ID: 19501622
[TBL] [Abstract][Full Text] [Related]
15. Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.
Quintel BK; Thomas A; Poer DeRaad DE; Slifka MK; Amanna IJ
Vaccine; 2019 Jul; 37(30):4214-4221. PubMed ID: 30606462
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.
Chaintoutis SC; Diakakis N; Papanastassopoulou M; Banos G; Dovas CI
Clin Vaccine Immunol; 2015 Sep; 22(9):1040-9. PubMed ID: 26178384
[TBL] [Abstract][Full Text] [Related]
17. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.
Schepp-Berglind J; Luo M; Wang D; Wicker JA; Raja NU; Hoel BD; Holman DH; Barrett AD; Dong JY
Clin Vaccine Immunol; 2007 Sep; 14(9):1117-26. PubMed ID: 17634508
[TBL] [Abstract][Full Text] [Related]
18. New avenues for therapeutic discovery against West Nile virus.
Sinigaglia A; Peta E; Riccetti S; Barzon L
Expert Opin Drug Discov; 2020 Mar; 15(3):333-348. PubMed ID: 32017639
[No Abstract] [Full Text] [Related]
19. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.
Magnusson SE; Karlsson KH; Reimer JM; Corbach-Söhle S; Patel S; Richner JM; Nowotny N; Barzon L; Bengtsson KL; Ulbert S; Diamond MS; Stertman L
Vaccine; 2014 Feb; 32(7):800-8. PubMed ID: 24380682
[TBL] [Abstract][Full Text] [Related]
20. Plant-made vaccines against West Nile virus are potent, safe, and economically feasible.
Chen Q
Biotechnol J; 2015 May; 10(5):671-80. PubMed ID: 25676782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
